Impact of disease progression on health-related quality of life of advanced ovarian cancer patients – Pooled analysis from the PRIMA trial

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

(2021) Michael Friedlander et al.   LANCET ONCOLOGY

738P Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial

(2021) M-P. Barretina-Ginesta et al.   ANNALS OF ONCOLOGY

Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs

(2020) Ashlyn Pinto et al.   VALUE IN HEALTH

Ovarian Cancer: An Integrated Review

(2019) Christine Stewart et al.   Seminars in Oncology Nursing

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

(2019) Antonio González-Martín et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study

(2019) Jack R Gallagher et al.   Future Oncology

Niraparib: A Review in Ovarian Cancer

(2018) Young-A Heo et al.   Targeted Oncology

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

(2018) Kathleen Moore et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future

(2017) Nicoletta Colombo et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Health-related quality of life in ovarian cancer patients and its impact on clinical management

(2011) Dana M Chase et al.   Expert Review of Pharmacoeconomics & Outcomes Research